Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions

다국어 초록 (Multilingual Abstract)

Multiple myeloma is a malignancy of B-cells that is characterized by the clonal expansion and accumulation of malignant plasma cells in the bone marrow. This disease remains incurable, and a median survival of 3-5 years has been reported with the use of current treatments. Viral-based therapies offer promising alternatives or possible integration with current therapeutic regimens. Among several gene therapy vectors and oncolytic agents, adenovirus has emerged as a promising agent, and it is already being used for the treatment of solid tumors in humans. The main concern with the clinical use of this vector has been its high immunogenicity; adenovirus is often able to induce a strong immune response in the host. Furthermore, new limitations in the efficacy of this therapy, intrinsic to the nature of tumor cells, have been recently observed. For example, our group showed a strong antiviral phenotype in vitro and in vivo in a subset of tumors, shedding new insights that may explain the partial failure of clinical trials based on this promising new therapy. In this review, we describe novel therapeutic approaches that implement viral-based treatments in hematological malignancies and address the novelty as well as the possible limitations of these new therapies, especially in the context of the use of adenoviral vectors for treating multiple myeloma.

참고문헌 (Reference)

• 1 Thirukkumaran CM, "Viral purging of haematological autografts: should we sneeze on the graft" 40 : 1-12, 2007
• 2 Carli PM, "Variation in survival of adult patients with haematological malignancies in Europe since 1978" 34 : 2253-2263, 1998
• 3 Surah S, "Utilization of HIV point-of-care testing clinics in general practice and genitourinary medicine services in south-east London" 20 : 168-169, 2009
• 4 Park BH, "Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial" 9 : 533-542, 2008
• 5 Harrington KJ, "Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers" 16 : 3067-3077, 2010
• 6 Marincola FM, "Tumors as elusive targets of T-cell-based active immunotherapy" 24 : 335-342, 2003
• 7 Delforge M, "Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues" 11 : 1086-1095, 2010
• 8 Greipp P, "Treatment paradigms for the newly diagnosed patient with multiple myeloma" 42 (42): S16-S21, 2005
• 9 Hale BG, "The multifunctional NS1 protein of influenza A viruses" 89 : 2359-2376, 2008
• 10 Muruve DA, "The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response" 452 : 103-107, 2008
• 11 zum Büschenfelde CM, "The generation of both T killer and Th cell clones specific for the tumor-associated antigen HER2 using retrovirally transduced dendritic cells" 167 : 1712-1719, 2001
• 12 Kawa A, "The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report" 57 : 79-81, 1987
• 13 Toshiro Shirakawa, "The Current Status of Adenovirus-based Cancer Gene Therapy" 한국분자세포생물학회 25 (25): 462-466, 2008
• 14 Sung RS, "TNFalpha and IFNgamma induced by innate anti-adenoviral immune responses inhibit adenovirus- mediated transgene expression" 3 : 757-767, 2001
• 15 Liu J, "Soluble Fms-like tyrosine kinase-1 expression inhibits the growth of multiple myeloma in nude mice" 39 : 499-506, 2007
• 16 Khodarev NN, "Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells" 67 : 9214-9220, 2007
• 17 Nociari M, "Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator" 81 : 4145-4157, 2007
• 18 Yamaguchi T, "Role of MyD88 and TLR9 in the innate immune response elicited by serotype 5 adenoviral vectors" 18 : 753-762, 2007
• 19 Bhardwaj A, "Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB- regulated antiapoptotic and cell survival gene products in human multiple myeloma cells" 109 : 2293-2302, 2007
• 20 Bluming AZ, "Regression of Burkitt's lymphoma in association with measles infection" 2 : 105-106, 1971
• 21 Turturro F, "Recombinant adenovirus-mediated cytotoxic gene therapy of lymphoproliferative disorders: is CAR important for the vector to ride" 10 : 100-104, 2003
• 22 Goel A, "Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene" 110 : 2342-2350, 2007
• 23 Nayak S, "Progress and prospects: immune responses to viral vectors" 17 : 295-304, 2010
• 24 Myers RM, "Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide" 82 : 700-710, 2007
• 25 Rogers JM, "Pleconaril. A broad spectrum antipicornaviral agent" 458 : 69-76, 1999
• 26 Thirukkumaran CM, "Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic" 70 : 2435-2444, 2010
• 27 Peng KW, "Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker" 101 : 2557-2562, 2003
• 28 Au GG, "Oncolytic coxsackievirus A21 as a novel therapy for multiple myeloma" 137 : 133-141, 2007
• 29 Pesonen S, "Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data" 8 : 12-28, 2011
• 30 Naschberger E, "Nuclear factor-kappaB motif and interferon-alpha-stimulated response element co-operate in the activation of guanylate-binding protein-1 expression by inflammatory cytokines in endothelial cells" 379 : 409-420, 2004
• 31 Sarkar SN, "Novel functions of proteins encoded by viral stress-inducible genes" 103 : 245-259, 2004
• 32 Kyle RA, "Multiple myeloma" 111 : 2962-2972, 2008
• 33 Bergelson JM, "Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5" 275 : 1320-1323, 1997
• 34 부경현, "Intrinsic Cellular Defenses against Virus Infection by Antiviral Type I Interferon" 연세대학교의과대학 51 (51): 9-17, 2010
• 35 Gollamudi R, "Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors" 28 : 641-649, 2010
• 36 Sadler AJ, "Interferon-inducible antiviral effectors" 8 : 559-568, 2008
• 37 Staeheli P, "Inhibition of vesicular stomatitis virus mRNA synthesis by human MxA protein" 65 : 4498-4501, 1991
• 38 Krug RM, "Inhibition of influenza viral mRNA synthesis in cells expressing the 1. interferon-induced Mx gene product" 56 : 201-206, 1985
• 39 Senac JS, "Infection and killing of multiple myeloma by adenoviruses" 21 : 179-190, 2010
• 40 Liikanen I, "Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus" 19 : 1858-1866, 2011
• 41 Seiler MP, "Immune response to helper dependent adenoviral mediated liver gene therapy: challenges and prospects" 7 : 297-305, 2007
• 42 Dingli D, "Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter" 103 : 1641-1646, 2004
• 43 Andreu P, "Identification of the IFITM family as a new molecular marker in human colorectal tumors" 66 : 1949-1955, 2006
• 44 Der SD, "Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays" 95 : 15623-15628, 1998
• 45 Fernandes MS, "Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene" 15 : 4847-4856, 2009
• 46 Ren SP, "Genetically modified myeloma cell vaccine inducing antitumor immune response in vivo" 14 : 54-60, 2006
• 47 Konstantinopoulos PA, "Gene- expression profiling in epithelial ovarian cancer" 5 : 577-587, 2008
• 48 Tsai MH, "Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation" 67 : 3845-3852, 2007
• 49 Dharmapuri S, "Engineered adenovirus serotypes for overcoming anti-vector immunity" 9 : 1279-1287, 2009
• 50 Martin DN, "Differences in the tumor microenvironment between African-American and European- American breast cancer patients" 4 : e4531-, 2009
• 51 Liu JM, "Determination of trace glucose and forecast of human diseases by affinity adsorption solid substrate- room temperature phosphorimetry based on triticum vulgaris lectin labeled with dendrimers-porphyrin dual luminescence molecule" 74 : 625-631, 2008
• 52 Wacher C, "Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses" 81 : 860-871, 2007
• 53 Appledorn DM, "Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors" 15 : 1606-1617, 2008
• 54 Msaouel P, "Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview" 11 : 43-53, 2009
• 55 Tong AW, "CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells" 36 : 543-558, 2000
• 56 Arendt BK, "Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2" 112 : 1931-1941, 2008
• 57 Rotbart HA, "Antiviral therapy for enteroviral infections" 18 : 632-633, 1999
• 58 Monsurró V, "Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy" 8 : 10-, 2010
• 59 Ni H, "Analysis of expression of nuclear factor kappa B (NF-kappa B) in multiple myeloma: downregulation of NF-kappa B induces apoptosis" 115 : 279-286, 2001
• 60 Weichselbaum RR, "An interferon- related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer" 105 : 18490-18495, 2008
• 61 Barlogie B, "Alexanian R. Plasma cell myeloma-new biological insights and advances in therapy" 73 : 865-879, 1983
• 62 Teoh G, "Adenovirus vector-based purging of multiple myeloma cells" 92 : 4591-4601, 1998
• 63 Meeker TC, "Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin's disease" 3 : 357-364, 1997
• 64 Györffy B, "A snapshot of microarray- generated gene expression signatures associated with ovarian carcinoma" 18 : 1215-1233, 2008
• 65 Forsyth P, "A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas" 16 : 627-632, 2008
• 66 Vidal L, "A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer" 14 : 7127-7137, 2008
• 67 Mastrangeli A, ""Sero-switch" adenovirus- mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype" 7 : 79-87, 1996